T1	p 133 191	patients with mixed dyslipidaemia and metabolic syndrome .
T2	p 403 418	syndrome ( MetS
T3	p 481 492	monotherapy
T4	p 498 506	moderate
T5	p 601 638	patients with mixed dyslipidaemia and
T6	p 657 716	previously randomised patients with low-density lipoprotein
T7	p 731 740	LDL-C ) >
T8	p 745 748	and
T9	p 752 779	> 200 mg/dl to rosuvastatin
T10	p 818 820	30
T11	p 823 825	or
T12	p 903 905	30
T13	p 987 1021	patients with MetS were included (
T14	i 16 43	rosuvastatin monotherapy or
T15	i 47 94	combination with fenofibrate or ?-3 fatty acids
T16	i 210 223	triglycerides
T17	i 458 492	high-dose rosuvastatin monotherapy
T18	i 514 558	combined with fenofibrate or ?-3 fatty acids
T19	i 767 794	rosuvastatin monotherapy 40
T20	i 804 805	R
T21	i 823 896	or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day ( RF group
T22	i 911 945	?-3 fatty acids 2 g/day ( R? group
T23	i 1048 1054	RF and
T24	i 1197 1200	3 %
T25	i 1205 1222	electrophoresis .
T26	i 1451 1452	)
T27	i 1491 1493	RF
T28	i 1516 1518	RF
T29	o 98 129	lipoprotein subfraction profile
T30	o 210 296	triglycerides ( TG ) , decreased high-density lipoprotein cholesterol ( HDL-C ) levels
T31	o 335 342	density
T32	o 403 411	syndrome
T33	o 566 597	lipoprotein subfraction profile
T34	o 705 736	lipoprotein cholesterol ( LDL-C
T35	o 741 744	160
T36	o 1046 1050	, RF
T37	o 1132 1163	lipoprotein subfraction profile
T38	o 1235 1248	mean LDL size
T39	o 1388 1416	hypotriglyceridemic capacity
T40	o 1448 1450	R?
T41	o 1469 1493	insulin resistance by RF
T42	o 1516 1554	RF significantly raised HDL-C levels (
T43	o 1610 1615	small
T44	o 1636 1647	cholesterol
T45	o 1651 1672	larger HDL subclasses
T46	o 1710 1714	R? .
T47	o 1750 1768	mean LDL size ; RF
T48	o 1847 1870	HDL subfraction profile